<> <http://www.w3.org/2000/01/rdf-schema#comment> "The repository administrator has not yet configured an RDF license."^^<http://www.w3.org/2001/XMLSchema#string> .
<> <http://xmlns.com/foaf/0.1/primaryTopic> <https://arxiv.universalpublishings.com/id/eprint/63803> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/AcademicArticle> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/Article> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/title> "CAR-T HUJAYRA TERAPIYASINING BOLALAR VA YOSH KATTALARDAGI OʻTKIR LIMFOBLASTIK LEYKEMIYADA TIMUSNING MORFOLOGIK VA MORFOMETRIK XUSUSIYATLARIGA TAʼSIRI: SISTEMATIK TAHLIL VA META-TAHLIL"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/ontology/bibo/abstract> "Ushbu keng qamrovli sistematik tahlil va meta-tahlil oʻtkir limfoblastik leykemiya (OʻLL) bilan kasallangan bolalar va yosh kattalarda (2–26 yosh) CD19-, CD22-, dual va allogeneic CAR-T hujayra terapiyasidan keyin timusning morfologik va morfometrik oʻzgarishlarini baholaydi. PRISMA 2020 yoʻriqnomasiga toʻliq rioya qilingan holda, 2025 yil 15 noyabrga qadar chop etilgan 23 tadqiqot (jami 1 846 bemor, shundan 1 423 nafari tisagenlecleucel olgan) kiritildi [1,7,9,18]. Random-effects model boʻyicha thymic rebound/hyperplasia chastotasi 76,8% (95% CI: 71,4–81,6%; I²=93%), yoshroq bemorlarda (&lt;16 yosh, 1 289 bemor) 88,7% (95% CI: 84,2–92,1%) ga yetdi. Timus hajmining standartlashtirilgan oʻrtacha farqi (SMD) +5,1 baravar (95% CI: 4,6–5,7; I²=91%, p&lt;0,001; 19 tadqiqot, 1 623 bemor). Gistologik subguruh (12 tadqiqot): Ki-67 indeksi oʻrtacha 52% (95% CI: 47–57%), Hassall tanachalari soni 3,2 baravar (95% CI: 2,8–3,6). Rebound+ guruhda 3 yillik EFS HR=0,28 (95% CI: 0,21–0,37; I²=82%), RFS HR=0,31 (95% CI: 0,23–0,42); ogʻir infektsiya RR=0,32 (95% CI: 0,25–0,41). Subguruh tahlili yosh, B-ALL fenotipi, ogʻir limfodepletsiya va CAR-T persistentsiyasi bilan reboundning kuchli bogʻliqligini tasdiqladi. Thymic rebound immun rekonstitutsiyaning eng ishonchli biomarkeridir va klinik monitoringda majburiy qoʻllanilishi kerak."^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/date> "2025-11-24" .
<https://arxiv.universalpublishings.com/id/org/ext-20ef1f289b7920027328009b5eefe52c> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Organization> .
<https://arxiv.universalpublishings.com/id/org/ext-20ef1f289b7920027328009b5eefe52c> <http://xmlns.com/foaf/0.1/name> "Center for Tech and Media Research"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/publisher> <https://arxiv.universalpublishings.com/id/org/ext-20ef1f289b7920027328009b5eefe52c> .
<https://arxiv.universalpublishings.com/id/publication/ext-d62a5dbdabc792c15cf76756361a4d36> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/ontology/bibo/Collection> .
<https://arxiv.universalpublishings.com/id/publication/ext-d62a5dbdabc792c15cf76756361a4d36> <http://xmlns.com/foaf/0.1/name> "Multidisciplinary Journal of Science and Technology"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/isPartOf> <https://arxiv.universalpublishings.com/id/publication/ext-d62a5dbdabc792c15cf76756361a4d36> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/ontology/bibo/status> <http://purl.org/ontology/bibo/status/published> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/creator> <https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/ontology/bibo/authorList> <https://arxiv.universalpublishings.com/id/eprint/63803#authors> .
<https://arxiv.universalpublishings.com/id/eprint/63803#authors> <http://www.w3.org/1999/02/22-rdf-syntax-ns#_1> <https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/creator> <https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/ontology/bibo/authorList> <https://arxiv.universalpublishings.com/id/eprint/63803#authors> .
<https://arxiv.universalpublishings.com/id/eprint/63803#authors> <http://www.w3.org/1999/02/22-rdf-syntax-ns#_2> <https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> .
<https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Person> .
<https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> <http://xmlns.com/foaf/0.1/givenName> "Dilshod"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> <http://xmlns.com/foaf/0.1/familyName> "Allaberganov"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/person/ext-9f063e69cafbf8155a9cdad66c562874> <http://xmlns.com/foaf/0.1/name> "Dilshod Allaberganov"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://xmlns.com/foaf/0.1/Person> .
<https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> <http://xmlns.com/foaf/0.1/givenName> "Maftuna"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> <http://xmlns.com/foaf/0.1/familyName> "Ruzieva"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/person/ext-ddbf2261a457c3782f14e47b7c9e0837> <http://xmlns.com/foaf/0.1/name> "Maftuna Ruzieva"^^<http://www.w3.org/2001/XMLSchema#string> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/EPrint> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://eprints.org/ontology/ArticleEPrint> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://purl.org/dc/terms/isPartOf> <https://arxiv.universalpublishings.com/id/repository> .
<https://arxiv.universalpublishings.com/id/eprint/63803> <http://www.w3.org/2000/01/rdf-schema#seeAlso> <https://arxiv.universalpublishings.com/id/eprint/63803/> .
<https://arxiv.universalpublishings.com/id/eprint/63803/> <http://purl.org/dc/elements/1.1/title> "HTML Summary of #63803 \n\nCAR-T HUJAYRA TERAPIYASINING BOLALAR VA YOSH KATTALARDAGI OʻTKIR LIMFOBLASTIK LEYKEMIYADA TIMUSNING MORFOLOGIK VA MORFOMETRIK XUSUSIYATLARIGA TAʼSIRI: SISTEMATIK TAHLIL VA META-TAHLIL\n\n" .
<https://arxiv.universalpublishings.com/id/eprint/63803/> <http://purl.org/dc/elements/1.1/format> "text/html" .
<https://arxiv.universalpublishings.com/id/eprint/63803/> <http://xmlns.com/foaf/0.1/primaryTopic> <https://arxiv.universalpublishings.com/id/eprint/63803> .